FDA 483 OBSERVATION · #14 OF 1,923 MOST-CITED
Plant construction and design
FDA cited this observation 944 times across 861 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The plant and its grounds were not constructed or designed to permit sanitary operations — insufficient space, poor layout, surfaces that cannot be cleaned, or grounds that create contamination or harborage.
Why FDA writes it — A plant that is not designed for sanitary operation makes contamination hard to prevent no matter how good the procedures are. Cleanability, adequate space to prevent cross-contamination, and controlled grounds are designed-in food-safety controls, so construction and design deficiencies are cited as root enablers of contamination.
- Maintain the grounds to prevent contamination — control harborage, drainage, and waste so pests and filth are not drawn to or held near the plant.
- Provide adequate space for equipment and storage of materials to allow sanitary operation and prevent cross-contamination.
- Use construction that allows floors, walls, and ceilings to be adequately cleaned and kept in good repair.
- Design fixtures, ducts, and pipes so drip or condensate does not contaminate food, surfaces, or packaging.
- Layout that forces raw and finished, or clean and dirty, flows to cross.
- Surfaces and structures not designed for cleaning, so sanitation can never be fully effective.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1× the rate of the average FDA-cited firm (8.0% vs 7.8%), across 861 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Your plant was not constructed to facilitate maintenance and sanitary operations.
Your plant was not constructed to facilitate maintenance and sanitary operations.
Your plant was not constructed to facilitate maintenance and sanitary operations.
Your plant was not constructed to facilitate maintenance and sanitary operations.
Your plant was not constructed to facilitate maintenance and sanitary operations.
Your plant was not constructed to facilitate maintenance and sanitary operations.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →